Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025

Accessibility StatementSkip Navigation SAN FRANCISCO. Sept. 9. 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdag: NKTR) announced todav that it will present results from the ongoing REZOLVE-AD Phase 2b study at the 2025 European Academy of Dermatology and Venereology (EADV) Congress being held in Paris, France from September 17-20, 2025. The presentation will include Phase 2b results on the primary and secondary endpoints from the 16-week induction phase of the REZOLVE-AD study, including multiple patient-re ...